Derived From Transgenic Multicellular Eukaryote (e.g., Plant, Etc.) Patents (Class 424/132.1)
-
Patent number: 8318907Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.Type: GrantFiled: February 1, 2010Date of Patent: November 27, 2012Assignee: Xencor, Inc.Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
-
Publication number: 20120288493Abstract: A method of inhibiting complement activation mediated by C3b inhibitors in a subject includes administering a C3B inhibitor to the subject to inhibit at least one of C3b binding to factors B and properdin, inhibit C3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of C3a, C5a, and MAC.Type: ApplicationFiled: May 18, 2012Publication date: November 15, 2012Inventor: Rekha Bansal
-
Patent number: 8258266Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: GrantFiled: May 27, 2009Date of Patent: September 4, 2012Assignee: Medarex, Inc.Inventors: Shrikant Deshpande, Haichun Huang, Mohan Srinivasan, Josephine M. Cardarelli, Changyu Wang, David B. Passmore, Vangipuram Rangan, Thomas E. Lane, Hans S. Keirstead, Michael T. Liu
-
Patent number: 8241626Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.Type: GrantFiled: October 3, 2006Date of Patent: August 14, 2012Assignee: Agensys, Inc.Inventors: Rene S. Hubert, Arthur B. Raitano, Douglas Saffran, Daniel E. H. Afar, Steven Chappell Mitchell, Mary Faris, Aya Jakobovits
-
Patent number: 8192737Abstract: The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc?RIIIA and/or Fc?RIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc?R is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.Type: GrantFiled: January 30, 2008Date of Patent: June 5, 2012Assignee: MacroGenics, Inc.Inventors: Jeffrey B. Stavenhagen, Sujata Vijh, Christopher Rankin
-
Publication number: 20120114635Abstract: The invention relates to antibodies that bind cross-linked amyloid ? oligomers, and methods for using such antibodies for diagnosis and treatment of Alzheimer's disease.Type: ApplicationFiled: June 7, 2011Publication date: May 10, 2012Applicant: The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Robert Moir, Rudolph E. Tanzi
-
Publication number: 20120117670Abstract: The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.Type: ApplicationFiled: May 11, 2010Publication date: May 10, 2012Applicant: U3 PHARMA GMBHInventors: Peter Wirtz, Jens Ruhe, Takeshi Takilzawa, Tomoko Takayama
-
Patent number: 8133486Abstract: The present invention provides a method for altering a B cell mediated pathology in a patient. This method comprises administering a composition comprising at least one and/or two chimeric proteins. Each chimeric protein comprises at least a portion of either the VH or VL region of a immunoglobulin molecule from particular B cells from a patient having a B cell mediated pathology, and an immunoglobulin constant region. The genes encoding VH and/or VL regions and the genes encoding immunoglobulin constant regions are isolated and inserted into an expression vector. The chimeric proteins are produced by introducing the expression vectors into insect cell lines. The chimeric proteins are purified using antibody affinity columns, and then chemically conjugated to an immunogenic carrier, keyhole-limpet hemocyanin (KLH).Type: GrantFiled: May 10, 2004Date of Patent: March 13, 2012Assignee: MMRGLOBAL, Inc.Inventors: Daniel P. Gold, Robert J. Shopes
-
Patent number: 8114966Abstract: The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method for preparing such antibodies, and a method for treating a mammal, preferably a human using such an antibody to provide for passive immunization.Type: GrantFiled: October 27, 2008Date of Patent: February 14, 2012Assignee: Forskarpatent I SYD ABInventors: Jan Nilsson, Roland Carlsson, Jenny Bengtsson, Leif Strandberg
-
Publication number: 20120034207Abstract: A method of making an antibody in plants that binds to a HER receptor is described. The antibody preferably contains sequences from trastuzumab that have been optimized for expression in plants.Type: ApplicationFiled: June 16, 2011Publication date: February 9, 2012Inventors: MICHAEL D. MCLEAN, FREYDOUN GARABAGI, J. CHRISTOPHER HALL
-
Publication number: 20110091450Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: October 15, 2010Publication date: April 21, 2011Applicants: OMEROS CORPORATION, UNIVERSITY OF LEICESTERInventors: Hans-Wilhelm Schwaeble, Thomas Dudler, Clark E. Tedford, James B. Parent, Gregory A. Demopulos
-
Publication number: 20100310552Abstract: The invention relates to transgenic avians which produce antibodies in the egg white by introducing a nucleic acid sequence into the genome of an avian embryo wherein the nucleic acid sequence comprises a nucleotide sequence encoding an antibody and to the antibodies and to methods related thereto.Type: ApplicationFiled: April 21, 2010Publication date: December 9, 2010Inventors: Jeffrey C. Rapp, Leandro Christmann, Markley C. Leavitt
-
Publication number: 20100303806Abstract: The invention encompasses among other things antibodies including cytotoxic antibodies such as anti-CD20 having avian N-linked glycosylation patterns obtained from egg white of eggs laid by transgenic avians.Type: ApplicationFiled: May 27, 2010Publication date: December 2, 2010Inventor: Alex J. Harvey
-
Publication number: 20100297110Abstract: The present invention relates to the use of an antibody or an antigen-binding fragment thereof with specific binding activity for human interleukin-4 for the prevention and/or treatment of cancer.Type: ApplicationFiled: March 21, 2007Publication date: November 25, 2010Applicant: APOGENIX GMBHInventors: Thomas Hoeger, Juergen Gamer, Giorgio Stassi, Matilde Todaro
-
Publication number: 20100272715Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.Type: ApplicationFiled: March 29, 2010Publication date: October 28, 2010Inventors: JEAN-MARIE SAINT-REMY, MARC JACQUEMIN
-
Patent number: 7790188Abstract: The present invention relates to an antifungal protein gene and cDNA sequence thereof, which is obtained by mining the whole genome sequences of Monascus pilosus BCRC 38072 and the unigene database. The gene can encode an antifungal protein MAFP1. A purified protein obtained from M. pilosus culture broth having molecular weight of about 7 kDa is identified as MAFP1 by N-terminal protein sequencing and comparative analysis. The purified MAFP1 protein can inhibit the growth of pathogens such as Paecilomyces variotii BCRC 33174 and Helminthosporium panici BCRC 35004. In addition, it is found by PCR test that the gene of this antifungal protein exists in other Monascus species such as M. Barkeri, M. floridanus, M. lunisporas, M. pilosus, M. ruber and the like. It is also been proved that the mafp1 gene and cDNA thereof in four Monascus strains, M. pilosus (BCRC 38072, BCRC 38093 and BCRC 31502) and M. ruber BCRC 31533, have the same DNA sequences.Type: GrantFiled: December 27, 2006Date of Patent: September 7, 2010Assignee: Food Industry Research and Development InstituteInventors: Ching-Yu Tu, Li-Ling Liaw
-
Patent number: 7786268Abstract: The invention relates to fully human antibodies, and fragments thereof, that bind to interferon-inducible-protein-10 (IP-10, CXCL10), thereby modulating the interaction between IP-10 and its receptor, CXCR3, and/or modulating the biological activities of IP-10. The invention also relates to the use of such anti-IP-10 antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.Type: GrantFiled: February 28, 2008Date of Patent: August 31, 2010Assignee: Novimmune SAInventors: Nicolas Fischer, Marie Kosco-Vilbois, Olivier Leger
-
Publication number: 20100183589Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, and to methods of making these isolated blood proteins and to therapeutic compositions comprising them.Type: ApplicationFiled: March 31, 2010Publication date: July 22, 2010Applicant: VENTRIA BIOSCIENCEInventors: Ning Huang, Raymond L. Rodriguez, Frank E. Hagie, David M. Stalker
-
Publication number: 20100015045Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: ApplicationFiled: July 16, 2009Publication date: January 21, 2010Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa A. Popp, Fortunata McConkey
-
Patent number: 7601818Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.Type: GrantFiled: July 15, 2004Date of Patent: October 13, 2009Assignees: Amgen, Inc., Medarex, Inc.Inventors: Kenneth D. Wild, Jr., James J. S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
-
Patent number: 7585522Abstract: A method for obtaining an immune response to a non-enteric pathogen antigen (NEPA) such as hepatitis B surface antigen (HBsAg) by feeding the antigen in a plant material to an animal that is immunoreceptive to the NEPA. It has now been discovered that the animal may be made immunoreceptive to the NEPA such as HBsAg by prior primary immunization. When the animal is made immunoreceptive by a prior, e.g. primary, immunization, an immune response to the NEPA may be boosted in the animal by feeding the animal the plant material containing the NEPA. For example, an animal, e.g. a human, that previously had a positive response to primary immunization against hepatitis B, can have a booster response to HBsAg by feeding the animal the antigen in a plant material. The plant material is a substance comprising a physiologically acceptable plant material, especially potatoes, containing the NEPA, e.g. hepatitis B surface antigen (HBsAg). The NEPA, e.g.Type: GrantFiled: December 16, 1999Date of Patent: September 8, 2009Assignee: Health Research, Inc.Inventor: Yasmin Thanavala
-
Publication number: 20090220494Abstract: The invention includes compositions comprising novel forms of glycosylated human interferon-?.Type: ApplicationFiled: October 15, 2007Publication date: September 3, 2009Inventors: Robert D. Ivarie, Alex J. Harvey, Julie A. Morris, Guodong Liu, Jeffrey C. Rapp
-
Patent number: 7572466Abstract: A method for obtaining an immune response to a non-enteric pathogen antigen (NEPA) such as hepatitis B surface antigen (HBsAg) by feeding the antigen in a plant material to an animal that is immunoreceptive to the NEPA. It has now been discovered that the animal may be made immunoreceptive to the NEPA such as HBsAg by administering the plant material containing the NEPA in conjunction with a suitable adjuvant. The plant material is a substance comprising a physiologically acceptable plant material, especially potatoes, containing the NEPA, e.g. hepatitis B surface antigen (HBsAg). The NEPA, e.g. HBsAg in the plant results from expression by the plant of the NEPA due to genetic alteration.Type: GrantFiled: December 16, 1999Date of Patent: August 11, 2009Assignees: Health Research, Inc., Boyce Thompson Institute for Plant Research, Inc.Inventors: Yasmin Thanavala, Charles Joel Arntzen, Hugh S. Mason
-
Publication number: 20090186017Abstract: A test method that provides data useful in predicting the probability of onset of acute graft-versus-host disease (GVHD) is described along with a kit for performing the method, and a pharmaceutical preparation and a molecular targeted therapy for treating or preventing GVHD. The test method includes measuring the blood DNAM-1 concentration of a patient of hematopoietic stem cell transplantation from bone marrow or the like over a period after the transplantation to provide data concerning the transition of the concentration to an abnormally high level deviating from the normal range, whereby the probability of the development of acute graft-versus-host disease is predicted, the risk of the development is estimated, or therapeutic effects after the development are evaluated.Type: ApplicationFiled: April 5, 2007Publication date: July 23, 2009Applicant: UNIVERSITY OF TSUKUBAInventors: Akira Shibuya, Hiroshi Kojima
-
Patent number: 7527810Abstract: A method for obtaining an immune response to hepatitis B surface antigen (HBsAg) by feeding the antigen in a plant material to an animal that is immunoreceptive to the HBsAg. It has now been discovered that the animal may be made immunoreceptive to HBsAg either by administering the plant material containing HBsAg in conjunction with a suitable adjuvant or by prior primary immunization. When the animal is made immunoreceptive by a prior, e.g. primary, immunization, an immune response to HBsAg may be boosted in the animal by feeding the animal the plant material containing the HBsAg. For example, an animal, e.g. a human, that previously had a positive response to primary immunization against hepatitis B, can have a booster response to HBsAg by feeding the animal the antigen in a plant material. The plant material is a substance comprising a physiologically acceptable plant material, especially potatoes, containing hepatitis B surface antigen (HBsAg).Type: GrantFiled: October 19, 1999Date of Patent: May 5, 2009Assignees: Health Research, Inc., Boyce Thompson Institute for Plant Research, IncInventors: Yasmin Thanavala, Charles Joel Arntzen, Hugh S. Mason
-
Publication number: 20090087428Abstract: The present application describes antibodies that selectively bind human Fc?RIIB, with little or no binding to other human Fc?Rs, e.g., human Fc?RIIA. The invention also provides isolated bispecific antibodies comprising an antibody that selectively binds Fc?RIIB, and a second antibody that specifically binds an activating receptor. Various uses, including therapeutic uses, for those antibodies are also described, including administration with anti-tumor antibodies and methods of inhibiting immune responses and suppressing histamine release.Type: ApplicationFiled: January 18, 2007Publication date: April 2, 2009Inventors: Andrew C. Chan, Robert L. Shields, Lawren Wu
-
Publication number: 20090053210Abstract: The present invention describes transgenic animals with human(ized) immunoglobulin loci and transgenes encoding human(ized) Ig? and/or Ig? sequences. Of particular interest are animals with transgenic heavy and light chain immunoglobulin loci capable of producing a diversified human(ized) antibody repertoire that have their endogenous production of Ig and/or endogenous Ig? and/or Ig? sequences suppressed. Simultaneous expression of human(ized) immunoglobulin and human(ized) Ig? and/or Ig? results in normal B-cell development, affinity maturation and efficient expression of human(ized) antibodies.Type: ApplicationFiled: August 27, 2007Publication date: February 26, 2009Inventor: Roland Buelow
-
Publication number: 20090041761Abstract: It is an object of the present invention to a method whereby a humoral immune response is induced more efficiently in producing an antibody against an antigen protein by gene immunization. A fusion gene composed of a gene encoding the full-length of a part of the antigen protein or a gene encoding a chaperonin subunit or a chaperonin subunit linkage linked thereto is administered to express the fusion gene in the animal, thereby inducing a humoral immune response to an antigen protein by administering. An example of the chaperonin includes Escherichia coli GroEL. There is also provided with a composition for immunization, a method for producing an antibody, a method for producing a hybridoma, and a method for producing a monoclonal antibody.Type: ApplicationFiled: October 14, 2005Publication date: February 12, 2009Inventors: Joe Chiba, Jun-ichi Hata, Naoki Nishiguchi, Masahiro Furutani
-
Publication number: 20080317743Abstract: The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody ? light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the nonhuman animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.Type: ApplicationFiled: June 16, 2008Publication date: December 25, 2008Inventors: Yoshimi Kuroiwa, Kazuma Tomizuka, Hitoshi Yoshida, Isao Ishida
-
Publication number: 20080299112Abstract: Substantially human antisera are provided by genetically modifying a domestic animal generally weighing at least about 1 kg. The domestic animal is genetically modified by generating inactive heavy and light chain immunoglobulin loci and integrating at least functional portions of the human heavy and light chain immunoglobulin loci, whereby the human loci generate an immune response. The antisera find use in the treatment of diseases, immunocompromised patients and in case of transplantation.Type: ApplicationFiled: August 8, 2008Publication date: December 4, 2008Inventor: Jens-Ulrich Buelow
-
Patent number: 7405275Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.Type: GrantFiled: September 24, 2004Date of Patent: July 29, 2008Assignee: Millennium Pharmaceuticals, Inc.Inventors: Shixin Qin, Nasim Kassam, Walter Newman
-
Patent number: 7384642Abstract: The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals, in particular dogs, against influenza.Type: GrantFiled: August 25, 2005Date of Patent: June 10, 2008Assignee: Merial LimitedInventors: Jules Maarten Minke, Kemal Karaca, Jiansheng Yao
-
Publication number: 20080124323Abstract: The present invention provides a method and composition for the treatment and/or prevention of respiratory tract infection and/or respiratory tract infection disease, said method comprising orally administering a composition to a mammal, said composition comprising a galactose containing indigestible oligosaccharide and at least 5 wt. % digestible galactose saccharide.Type: ApplicationFiled: August 24, 2005Publication date: May 29, 2008Inventors: Gunther Boehm, Laura M'Rabet, Bernd Stahl, Johan Garssen
-
Publication number: 20080118501Abstract: The invention relates, in part, to antibodies with increased ADCC activity. Methods of producing such antibodies are also provided. The antibodies of the invention are produced in mammary epithelial cells, such as those in a non-human transgenic animal engineered to express and secrete the antibody in its milk. The antibodies or compositions comprising the antibodies can be used to treat disease in which ADCC activity provides a benefit. In one embodiment, therefore, the antibodies or compositions comprising the antibodies can be used to treat cancer, lymphoproliferative disease or autoimmune disease.Type: ApplicationFiled: October 23, 2006Publication date: May 22, 2008Applicant: GTC Biotherapeutics, Inc.Inventors: Daniel Schindler, Harry M. Meade, Timothy Edmunds, John McPherson
-
Patent number: 7118741Abstract: There is disclosed a synthetic cross-linker protein capable of binding a molecule or macromolecular species to a transcytosis receptor for transport of the molecule or macromolecule species across a mucous membrane, said cross-linker protein comprising a first binding region capable of binding selectively to a site on the said molecule or macromolecular species to be transported and a second binding region capable of binding selectively to a site on said receptor, wherein the first binding region is the antigen-binding site of a first antibody molecule having specificity for an antigenic site on said molecule or macromolecular species to be transported and the second binding region is the antigen-binding site of a second antibody molecule which has specificity for an antigenic site on the said transcytosis receptor.Type: GrantFiled: May 13, 1996Date of Patent: October 10, 2006Assignee: The National Blood AuthorityInventors: Jacqueline Elizabeth Mary Gilmour, David Joseph Unsworth
-
Patent number: 6852319Abstract: The present invention relates to expression and assembly of foreign multimeric proteins—e.g., antibodies—in plants, as well as to transgenic plants that express such proteins. In one of several preferred embodiments, the generation and assembly of functional secretory antibodies in plants is disclosed. The invention also discloses compositions produced by the transgenic plants of the present invention and methods of using same.Type: GrantFiled: January 25, 2000Date of Patent: February 8, 2005Assignee: The Scripps Research InstitueInventors: Mich B. Hein, Andrew Hiatt, Julian K-C Ma
-
Publication number: 20040265300Abstract: A chimeric polypeptide has the formula: pTox-pTarg, wherein pTox is a viral apoptotic peptide, such as the Vpr peptide of HIV-1 or a fragment of the Vpr peptide of HIV-1 containing the amino acid motif H(F/S)RIG that interacts with mitochondrial inner membrane, adenine nucleotide translocation (ANT) protein of a cell. pTarg is an antibody or an antibody fragment that binds to the outer membrane of the cell. Binding of the chimeric polypeptide to the cell is followed by apoptosis of the cell. A vector encoding a chimeric polypeptide and a recombinant host cell comprising the vector are provided. The chimeric polypeptide us useful for targeting pTox to cells, such as cancer cells.Type: ApplicationFiled: July 28, 2003Publication date: December 30, 2004Inventors: Lena Edelman, Etienne Daniel Francois Jacotot, Jean-Paul Briand
-
Publication number: 20040258684Abstract: Modified antibodies containing 2 or more H chain V domains and or more L chain V domains of a monoclonal antibody which can transduce a signal into cells by crosslinking a cell surface molecule, thereby serving as an agonist. Because of being usable as agonists for signal transduction, these modified antibodies are useful as, for example, preventives and/or remedies for various diseases such as cancer, inflammation, hormone disorders and blood diseases.Type: ApplicationFiled: October 7, 2002Publication date: December 23, 2004Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Naoshi Fukushima, Masayuki Tsuchiya, Masayoshi Oh-eda, Shinsuke Uno, Yasufumi Kikuchi, Toshihiko Ohtomo
-
Publication number: 20040253231Abstract: The present invention provides NB-ARC and CARD-containing proteins (NACs), nucleic acid molecules encoding NACs and antibodies specific for at least one NAC. The invention further provides chimeric NAC proteins. The invention also provides screening assays for identifying an agent that can effectively alter the association of a NAC with a NAC-associated protein. The invention further provides methods of modulating apoptosis in a cell by introducing into the cell a nucleic acid molecule encoding a NAC or an antisense nucleotide sequence. The invention also provides a method of using a reagent that can specifically bind to a NAC to diagnose a pathology that is characterized by an increased or decreased level of apoptosis in a cell.Type: ApplicationFiled: April 20, 2004Publication date: December 16, 2004Applicant: The Burnham InstituteInventor: John C. Reed
-
Publication number: 20040247590Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A&bgr; in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A&bgr; and antibodies binding to the same.Type: ApplicationFiled: July 13, 2004Publication date: December 9, 2004Applicant: Neuralab LimitedInventors: Dale B. Schenk, Frederique Bard, Theodore Yednock
-
Patent number: 6818213Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.Type: GrantFiled: July 12, 1999Date of Patent: November 16, 2004Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Sophia Ran, Rolf A. Brekken
-
Publication number: 20040213779Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.Type: ApplicationFiled: August 15, 2003Publication date: October 28, 2004Inventors: Philip E. Thorpe, M. Melina Soares, Sophia Ran
-
Patent number: 6803039Abstract: Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.Type: GrantFiled: May 16, 2001Date of Patent: October 12, 2004Assignee: Japan Tobacco Inc.Inventors: Takashi Tsuji, Katsunari Tezuka, Nobuaki Hori
-
Publication number: 20040185040Abstract: The invention provides methods for modulating the immune system using anti-CD83 antibodies that can influence CD83 function.Type: ApplicationFiled: November 21, 2003Publication date: September 23, 2004Applicant: Celltech R & D LimitedInventors: Leon Fernando Garcia-Martinez, Yuching Chen, Dawn Andrews
-
Publication number: 20040180046Abstract: The present invention relates to bispecific molecules that are characterized by having a first binding domain which binds an antigen present in the circulation of a mammal and a second binding domain which binds the C3b-like receptor (known as complement receptor 1 (CR1) or CD35 in primates). The bispecific molecules do not consist of a first monoclonal antibody to CR1 that has been chemically cross-linked to a second monoclonal antibody. The invention also relates to methods of making the bispecific molecules and therapeutic uses thereof, as well as to kits containing the bispecific molecules. The invention further provides polyclonal populations of bispecific molecules, which comprise populations of bispecific molecules with different antigen recognition specificities. Such polyclonal populations of bispecific molecules can be used for targeting multiple epitopes of a pathogenic antigenic molecule and/or multiple variants of a pathogenic antigenic molecule.Type: ApplicationFiled: March 3, 2004Publication date: September 16, 2004Inventor: Jeff Himawan
-
Publication number: 20040156844Abstract: The present invention provides an oral dosage form including a medicament and an insoluble component adhered to or encapsulates the medicament that is susceptible to cleavage by colonic bacteria and resistant to cleavage by intestinal saccharidases.Type: ApplicationFiled: November 20, 2003Publication date: August 12, 2004Inventor: Curtis Wright
-
Publication number: 20040151719Abstract: Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.Type: ApplicationFiled: March 4, 2004Publication date: August 5, 2004Applicant: Human Genome Sciences, Inc.Inventors: Yi Li, Steven M. Ruben
-
Publication number: 20040146505Abstract: The invention relates to the use of a polypeptide which comprises i) a first portion comprising the part of human Fc which binds to CD64, and ii) a second portion comprising one or more heterologous T cell epitopes for stimulating a cytotoxic T cell response. The polypeptide may be an antibody which may be used to stimulate an cytotoxic T cell response against pathogens and tumour cells in patients in need of such treatment.Type: ApplicationFiled: January 21, 2004Publication date: July 29, 2004Inventors: Linda Gillian Durrant, Tina Parsons, Adrian Robins
-
Publication number: 20040136980Abstract: The present invention relates to a synthetic variable region of an immunoglobin construct which contains in at least one of its CDRs a sequence of thrombopoietin, <i>e.g.</i>, IEGPTLRQWLAARA or its derivatives. This construct can efficiently bind and activate a thrombopoientin receptor (MPL) leading to stimulation of proliferation, growth or differentiation or modulation of apoptosis of hematopoietic cells, especially platelet progenitor cells. The invention further relates to the use of the synthebody to treat hematopoietic or immune disorders, and particularly thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions.Type: ApplicationFiled: August 25, 2003Publication date: July 15, 2004Inventors: Daniel A Soltis, Ronald M. Burch, Robert A. Ogert
-
Publication number: 20040091475Abstract: The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking TPO receptor to thereby exert TPO agonist action. The modified antibody can be used as a TPO signal transduction agonist and, therefore, useful as a preventive and/or remedy for various diseases such as platelet-reduction-related blood diseases, thrombopenia following chemotherapy for cancer or leukemia, etc.Type: ApplicationFiled: April 17, 2003Publication date: May 13, 2004Inventors: Masayuki Tsuchiya, Toshihiko Ohtomo, Naohiro Yabuta, Hiroyuki Tsunoda, Tetsuro Orita